FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2514-2516 June 5, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mallal, S. PubMed Citation

To the Editor: The Prospective Randomized Evaluation of DNA Screening in a Clinical Trial (PREDICT-1) by Mallal et al. (Feb. 7 issue)¹ showed that screening for HLA-B*5701 resulted in a significant reduction in the rate of hypersensitivity reactions (from 7.8% to 3.4%) among patients who were positive for the human immunodeficiency virus (HIV) and were receiving abacavir. However, because of methodologic limitations, this study will only modestly alter clinical practice. In the HLA-B*5701–negative group, all patients appeared to have a negative epicutaneous patch test (immunologic confirmation of a hypersensitivity reaction to abacavir). Notwithstanding the risks associated with rechallenge,² the investigators . . . [Full Text of this Article]

This article has been cited by other articles:

• Hughes, C. A, Foisy, M. M, Dewhurst, N., Higgins, N., Robinson, L., Kelly, D. V, Lechelt, K. E (2008). Authors' Reply. The Annals of Pharmacotherapy 42: 1520-1521 [Full Text]